Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study.

Iyo, Masaomi; Ishigooka, Jun; Nakamura, Masatoshi; Sakaguchi, Reiko; Okamoto, Keisuke; Mao, Yongcai; Tsai, Joyce; Fitzgerald, Alison; Takai, Kentaro; Higuchi, Teruhiko

Iyo, Masaomi; Ishigooka, Jun; Nakamura, Masatoshi; Sakaguchi, Reiko; Okamoto, Keisuke; Mao, Yongcai; Tsai, Joyce; Fitzgerald, Alison; Takai, Kentaro; Higuchi, Teruhiko.

Afiliação

Iyo M; Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ishigooka J; Institute of CNS Pharmacology, Tokyo, Japan.
Nakamura M; Department of Data Science, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan.
Sakaguchi R; Department of Clinical Research, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan.
Okamoto K; Department of Clinical Operation, Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan.
Mao Y; Division of Data Science, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.
Tsai J; Division of Clinical Research, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.
Fitzgerald A; Division of Clinical Operations, Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.
Takai K; Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan.
Higuchi T; Japan Depression Center, Tokyo, Japan.